Group items tagged

Quantifying human calcium absorption using pharmacokinetic methods. Heaney RP. J Nutr. 2003 Apr;133(4):1224-6. PMID: 12672947

Pharmacokinetics of a single, large dose of cholecalciferol. Ilahi M, Armas LA, Heaney RP. Am J Clin Nutr. 2008 Mar;87(3):688-91. PMID: 1832660 Conclusions: Cholecalciferol (100 000 IU) is a safe, effective, and simple way to increase calcidiol concentrations. The dosing interval should be ≤2 mo to ensure continuous serum calcidiol concentrations above baseline. Our study highlights that 100 000 IU cholecalciferol is a safe, efficient, and cost-effective means to increase calcidiol concentrations in the elderly. From this study we can safely recommend 100 000 IU cholecalciferol dosed every 2 mo in persons with moderate baseline calcidiol concentrations. However, in those persons with baseline calcidiol concentrations < 20 ng/mL, even this large dose will not adequately raise their calcidiol concentrations.

Pharmacokinetics of vitamin D toxicity. Jones G. Am J Clin Nutr. 2008 Aug;88(2):582S-586S. Review. PMID: 18689406

Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers.\nAlmeida L, Vaz-da-Silva M, Falcão A, Soares E, Costa R, Loureiro AI, Fernandes-Lopes C, Rocha JF, Nunes T, Wright L, Soares-da-Silva P.\nMol Nutr Food Res. 2009 Feb 4. [Epub ahead of print]\nPMID: 19194969

Dr. Milne presented data which showed that SRT501, Sirtris' proprietary formulation of resveratrol, reduces glucose and improves insulin sensitivity in multiple pre-clinical models of Type 2 Diabetes. Dr. Milne also presented pharmacokinetic (PK) data fro

Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo.\nChen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, Choyke PL, Pooput C, Kirk KL, Buettner GR, Levine M.\nProc Natl Acad Sci U S A. 2007 May 22;104(21):8749-54. Epub 2007 May 14.\nPMID: 17502596 \n doi: 10.1073/pnas.0702854104\n

Phosphatidylserine. Monograph.\nAltern Med Rev. 2008 Sep;13(3):245-7. \nPMID: 18950250 [PubMed - indexed for MEDLINE]

Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders. Kulkami SK et al. Phytotherapy Research, Published Online: 8 Dec 2009 This review attempts to discuss the pharmacological basis of the use of berberine in various central nervous system and related disorders. Its protective effect in Alzheimer's, cerebral ischemia, mental depression, schizophrenia and anxiety are highlighted. However, more detailed clinical trials along with a safety assessment of berberine are warranted for positioning the alkaloid in the treatment of neurological disorders.